The Latest Trading Price of Kopran Ltd is ₹ 164.7 as of 30 Apr 15:30
. The P/E Ratio of Kopran Ltd changed from 7.4 on March 2021 to 21.9 on March 2025 . This represents a CAGR of 24.23% over 5 yearsThe P/E Ratio of Wanbury Ltd changed from 3.4 on March 2022 to 25.2 on March 2025 . This represents a CAGR of 65.00% over 4 years The Market Cap of Kopran Ltd changed from ₹ 453.94 crore on March 2021 to ₹ 845.48 crore on March 2025 . This represents a CAGR of 13.25% over 5 yearsThe Market Cap of Wanbury Ltd changed from ₹ 207.5 crore on March 2021 to ₹ 768.96 crore on March 2025 . This represents a CAGR of 29.95% over 5 years The revenue of Kopran Ltd for the Dec '25 is ₹ 194.35 crore as compare to the Sep '25 revenue of ₹ 117.93 crore. This represent the growth of 64.8% The revenue of Wanbury Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Kopran Ltd for the Dec '25 is ₹ 17.83 crore as compare to the Sep '25 ebitda of ₹ -5.25 crore. This represent the decline of -439% The ebitda of Wanbury Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Kopran Ltd changed from ₹ 11.1 crore to ₹ 9.34 crore over 7 quarters. This represents a CAGR of -9.39%
The net profit of Wanbury Ltd changed from ₹ 1.04 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00%
The Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 53.94 % on March 2025 . This represents a CAGR of -0.49% over 5 yearsThe Dividend Payout of Wanbury Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Kopran Ltd
Kopran Limited, incorporated on April 26, 1958, was promoted by the Somani group and is a group company of Parijat Enterprises.
Company operates in two distinct business verticals.
While pharmaceutical formulations production is managed by Kopran Limited, manufacturing of API is operated under Kopran Research Laboratories Limited (KRLL).
Company specialise in developing and manufacturing Penicillin and non-penicillin-based drugs.
Leveraging cutting-edge technology, it manufactures highquality finished dosage drugs that adhere to international requirements.
About Wanbury Ltd
Wanbury Limited, formerly known Pearl Organics Limited was incorporated in August, 1988.
The Company attained its present name in September 2004.
The Company is engaged in the business of pharmaceutical and related activities, including research.
The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs.
In 1995, the Company acquired plant of Brij Chemicals Pvt Ltd at Patalganga.
In 1996, it entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US.
In 2007-08, the merger of Doctors Organic Chemicals Limited (DOCL) with the Company became effective from 1st April, 2007.
FAQs for the comparison of Kopran Ltd and Wanbury Ltd
Which company has a larger market capitalization, Kopran Ltd or Wanbury Ltd?
Market cap of Kopran Ltd is 795 Cr while Market cap of Wanbury Ltd is 901 Cr
What are the key factors driving the stock performance of Kopran Ltd and Wanbury Ltd?
The stock performance of Kopran Ltd and Wanbury Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Kopran Ltd and Wanbury Ltd?
As of May 4, 2026, the Kopran Ltd stock price is INR ₹164.7. On the other hand, Wanbury Ltd stock price is INR ₹257.9.
How do dividend payouts of Kopran Ltd and Wanbury Ltd compare?
To compare the dividend payouts of Kopran Ltd and Wanbury Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.